Posted by Michael Wonder on 10 Aug 2023
Health Canada approves Alhemo (concizumab injection) for the treatment of patients living with haemophilia A with FVIII inhibitors
9 August 2023 - Health Canada has approved a new indication for Alhemo (concizumab injection) for the treatment of Canadian adolescent and adult patients with haemophilia A (congenital factor VIII deficiency) who have FVIII inhibitors.
Alhemo was first approved by Health Canada in March 2023 for the treatment of patients who have FIX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
